Skip to main content
. 2009 Aug 10;2009:105376. doi: 10.1155/2009/105376

Table 2.

Percent of Days with HSV-2 Viral Shedding.

Population ITTC Valacyclovir Placebo P-value % Reduction
(n = 52) (n = 52)
Period 1 n 25 27
Mean (SD %) 3.0 (4.6) 14.3 (16.6)
Range 0–17 0–68

Period 2 n 27 25
Mean (SD %) 2.9 (6.5) 12.6 (17.4)
Range 0–29 0–61

Overall n 52 52
Mean (SD %) 2.9 (5.6) 13.5 (16.9) <.001 78
Range 0–29 0–68

ITT Period 1 n 30 35 <.001 83
Mean (SD %) 2.6 (4.3) 14.9 (18.3)

Other Efficacy Parameters

ITTC Valacyclovir (n = 52) Placebo (n = 52) P-value

Percent days with subclinical shedding, Mean (SD %) 2.4 (4.8) 11 (15.1) <.001
Percent days with clinical shedding, Mean (SD %) 0.6 (1.7) 2.4 (4.4) .014
Subjects with no Shedding, n (%) 31 (60) 15 (29) <.001
Proportion of subjects recurrencefree, n (%) 41 (79) 27 (52) .003
Median time to first genital herpes recurrencea (days) >68 61 .010

aFirst treatment period.